Analysis of the main directions of therapeutic regimens for the treatment of helminthiases of the digestive system given in the new clinical treatment protocols
DOI:
https://doi.org/10.24959/cphj.20.1523Keywords:
analysis, treatment regimen, clinical protocol, helminthiasisAbstract
The treatment of helminthiases of the digestive system is a socially significant problem that is urgent for many countries in the world, including Ukraine. Over the last 5 years, cases of enterobiosis, ascariasis and trichocephalosis have been reported most frequently in Ukraine. Therefore, it is advisable to update and implement the latest treatment protocols for the specified pathology.
Aim. To analyze recommendations for the treatment of helminthiasis of the digestive system, which are given in the new clinical protocols, and identify the promising directions for saturation of the domestic pharmaceutical market with drugs that meet the needs of patients with this pathology.
Materials and methods. The objects of the study were guidelines for the treatment of helminthiases of the digestive system in the open access on the website of the Ministry of Health of Ukraine, scientific publications of domestic and foreign authors and our own research. The methods of generalization, systematization of theoretical and practical material, bibliosemantic and systematic analysis were used in the work.
Results. The study of recommendations for the treatment of enterobiosis, ascariasis, intestinal cestodes, strongyloidosis, nematodosis and trichocephalosis has shown that the drug of choice for the treatment of this group of diseases is albendazole, which is included in each treatment protocol. Mebendazole is recommended for use in all regimens, except for the treatment of strongyloidosis. Drugs of other pharmaceutical ingredients are recommended for administration in rare cases. The main types of the pharmacological activity and side effects of albendazole are given.
Conclusions. The treatment regimens recommended for helminthiasis of the digestive system have been analyzed, and the substances, based on which the development of domestic anthelmintic drugs is rational, have been determined.References
Nastanova 01040. Vstup do temy kyshkovykh helmintiv. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01040&format=pdf
Nastanova 00019. Hostryky (enterobioz). (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00019&format=pdf
Nastanova 00020. Askarydoz. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00020&format=pdf
Nastanova 00021. Kyshkovi tsestodozy. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00021&format=pdf
Nastanova 01038. Stronhiloyidoz. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01038&format=pdf
Nastanova 01039. Nematodozy. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01039&format=pdf
Nastanova 01043. Trykhotsefalʹoz. (2017). Duodecim Medical Publications Ltd. Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01043&format=pdf
Albenza (albendazole) drug. (2019). Rxlist. Available at: https://www.rxlist.com/albenza-drug.htm#description
Abbas A., Newsholme W. (2009). Prescriber, 3, 31-41.
Broek I., Harris N., Henkens M. et al. (2013). Clinical guidelines. Diagnosis and treatment manual. 2013 ed. Médecins Sans Frontières, 334.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
